Organization (Industry)
Harmony Biosciences Holdings, Inc.
ClinicalTrials.gov lists Harmony Biosciences Holdings, Inc. as lead sponsor of 16 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
20 sections measured, none recorded
This page covers Harmony Biosciences Holdings, Inc. and 1 company grouped under it: 16 lead-sponsored trials (0 its own, 16 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Harmony Biosciences Management, Inc. | 16 | 0 |
Financing and grant events (6)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-02-25 | Follow-on offering | 200,000,000 | Edgar offerings |
| 2024-10-31 | Follow-on offering | 285,200,000 | Edgar offerings |
| 2024-10-29 | Other financing | not disclosed | Edgar offerings |
| 2021-11-09 | Other financing | not disclosed | Edgar offerings |
| 2021-11-09 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 6 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Latest dated events (7)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-02-25 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-10-31 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-10-29 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2022-04-01 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2021-11-09 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 7 events.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, disease areas, trials by start year as sponsor or collaborator, active development programs, approved assets, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.